Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 29.06.2026 1 AJR Am J Roentgenol 2 BMC Cancer 1 BMC Urol 1 Cancer Imaging 1 Clin Cancer Res 1 Clin Imaging 4 Eur Radiol 1 Eur Urol 4 Int J Radiat Oncol Biol Phys 2 J Clin Oncol 1 J Nucl Med 2 J Urol 1 PLoS One 1 Prostate 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. PEACOCK JG, Franquet-Elia E, Harris AL, Weeks JG, et al
   A Practical Guide to PSMA PET Radiopharmaceuticals for Prostate Cancer Imaging, From the AJR Special Series on Molecular Imaging.
   AJR Am J Roentgenol. 2026 Jun 24. doi: 10.2214/AJR.26.34730.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. MA L, Fan L, Luo X, Huang Z, et al
   Exploring the relationship between potential hepatotoxicity and novel hormonal therapies in prostate cancer: a systematic review and meta-analysis.
   BMC Cancer. 2026 Jun 23. doi: 10.1186/s12885-026-16339.
   PubMed         Abstract available
   
   
3. DAI T, Xu Z, Wang H, Han W, et al
   Pharmacokinetics, safety, and efficacy of fuzuloparib in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: a phase 1 dose escalation and expansion study.
   BMC Cancer. 2026 Jun 25. doi: 10.1186/s12885-026-16182.
   PubMed         Abstract available
   
   

   
   BMC Urol

4. FRANZ T, Sicker T, Lueke J, Dinh B, et al
   To biopsy or not biopsy, that is the question - PI-RADS 3 prostate lesions - validation of clinical and radiological parameters for biopsy decision-making.
   BMC Urol. 2025;25:274.
   PubMed         Abstract available
   
   

   
   Cancer Imaging

5. CHO S, Seo HJ, Han H, Lee S, et al
   The feasibility of [(18)F]PSMA-1007 PET/CT for response assessment in prostate cancer following neoadjuvant androgen deprivation therapy compared with mpMRI.
   Cancer Imaging. 2026 Jun 23. doi: 10.1186/s40644-026-01073.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

6. MEDINA S, Tokuyama N, Putcha V, Pathak T, et al
   AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.
   Clin Cancer Res. 2026 Jun 26. doi: 10.1158/1078-0432.CCR-26-0871.
   PubMed         Abstract available
   
   

   
   Clin Imaging

7. PALUSZEK O, Almengo K, Saunders J, Pitsoulakis E, et al
   Availability, quality, and understandability of English and Spanish-language YouTube content on PSMA PET imaging for prostate cancer.
   Clin Imaging. 2026;137:110871.
   PubMed        
   
   

   
   Eur Radiol

8. DIAS AB, Barentsz J, Allen C, Baroni RH, et al
   Prostate MRI quality improvement: a Roadmap from the ESUR Prostate MRI Working Group.
   Eur Radiol. 2026;36:5728-5744.
   PubMed         Abstract available
   
   
9. SUSHENTSEV N, Arya Z, Budd J, Frary A, et al
   AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study.
   Eur Radiol. 2026;36:5719-5727.
   PubMed         Abstract available
   
   
10. THORLEY N, Parry T, Brembilla G, Giganti F, et al
    Diagnostic accuracy of a 'stage-gated' approach for reporting prostate screening MRI: "Is less more?".
    Eur Radiol. 2026;36:5678-5687.
    PubMed         Abstract available
    
    
11. MESSINA E, Borrelli A, Mezzapesa F, Laschena L, et al
    Artificial intelligence-assisted reading of non-contrast prostate MRI: application and concordance with expert interpretation in a screening population within the PROSA trial.
    Eur Radiol. 2026;36:5690-5700.
    PubMed         Abstract available
    
    

    
    Eur Urol

12. MA H, Zhang L
    Re: Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men with Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE).
    Eur Urol. 2026 Jun 23:S0302-2838(26)02215-3. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Int J Radiat Oncol Biol Phys

13. DUAN J, Zhu L, Cardan RA, Rong Y, et al
    Deformable Point Cloud Registration-Based Bidirectional Local Distance (DPCR-BLD): A Methodology for Systematic Evaluation and Visualization of Local Disagreements in Clinical Autocontouring.
    Int J Radiat Oncol Biol Phys. 2026;125:1258-1270.
    PubMed         Abstract available
    
    
14. NIKITAS J, Jamshidian P, Tree AC, Hall E, et al
    Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.
    Int J Radiat Oncol Biol Phys. 2026;125:1140-1148.
    PubMed         Abstract available
    
    
15. MEYER J, Zoberi JE, Kim H, Tran A, et al
    A National Survey of Medical Physicists: Part 1-Practice Patterns for High-Dose-Rate Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2026;125:1228-1240.
    PubMed         Abstract available
    
    
16. AL-HALLAQ HA, Zoberi JE, Tran A, Kim H, et al
    A National Survey of Medical Physicists: Part 2-Assessing Work Effort and Perceived Challenges and Satisfaction in HDR Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2026;125:1241-1251.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

17. RIAZ IB, Rumble RB, Hope TA, Procopio G, et al
    Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2026 Jun 22:JCO2601001. doi: 10.1200/JCO-26-01001.
    PubMed        
    
    
18. VASCOTTO IA, Antonica F, Roviello G, Antonuzzo L, et al
    Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2026 Jun 22:JCO2600658. doi: 10.1200/JCO-26-00658.
    PubMed        
    
    

    
    J Nucl Med

19. KASHYAP R, Buteau JP, Papa N, Ayati N, et al
    Prognostic Value of Restaging [(18)F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Therapy.
    J Nucl Med. 2026 Jun 25:jnumed.126.272531. doi: 10.2967/jnumed.126.272531.
    PubMed         Abstract available
    
    

    
    J Urol

20. TYAGI P
    Letter: Testosterone Does Not Drive Prostate Cancer: Presenting the New Framework of Androgen Adequacy vs Inadequacy.
    J Urol. 2026 Jun 25:101097JU0000000000005160. doi: 10.1097/JU.0000000000005160.
    PubMed        
    
    
21. CAMPBELL JA, Ali D, Rezaee ME, Jing Y, et al
    The Effect of Prostate Volume and 5-Alpha Reductase Inhibitor Use on Grade Progression and Treatment Decisions in Patients with Prostate Cancer on Active Surveillance.
    J Urol. 2026 Jun 24:101097JU0000000000005182. doi: 10.1097/JU.0000000000005182.
    PubMed         Abstract available
    
    

    
    PLoS One

22. OU Y, Ye C, Jiang H, Zhu Y, et al
    Tumor-associated M2 macrophages promote prostate cancer invasion through the M-CSF-PCLAF pathway.
    PLoS One. 2026;21:e0351858.
    PubMed         Abstract available
    
    

    
    Prostate

23. QUARTA L, Petix M, Filzmayer M, Orlandi F, et al
    Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity.
    Prostate. 2026 Jun 23. doi: 10.1002/pros.70211.
    PubMed         Abstract available
    
    

    
    Semin Oncol

24. PETRELLI F, Motta F, Bodrato S, De Stefani A, et al
    PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.
    Semin Oncol. 2026;53:152504.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum